Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Anthony Elias

Concepts (664)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
108
2024
2239
6.180
 Why?
Antineoplastic Combined Chemotherapy Protocols
96
2025
1683
4.170
 Why?
Sarcoma
33
2025
191
3.900
 Why?
Receptors, Estrogen
22
2021
436
2.350
 Why?
Triple Negative Breast Neoplasms
14
2024
201
2.290
 Why?
Receptor, ErbB-2
22
2024
342
2.050
 Why?
Hematopoietic Stem Cell Transplantation
36
2011
615
2.010
 Why?
Carcinoma, Small Cell
19
2003
172
1.730
 Why?
Soft Tissue Neoplasms
14
2022
114
1.600
 Why?
Carcinoma, Ductal, Breast
7
2018
83
1.510
 Why?
Neoadjuvant Therapy
17
2024
403
1.350
 Why?
Antineoplastic Agents
31
2023
2129
1.250
 Why?
Neoplasm Recurrence, Local
20
2022
1055
1.180
 Why?
Neoplasm Staging
35
2024
1373
1.070
 Why?
Receptors, Progesterone
13
2020
349
1.060
 Why?
Lung Neoplasms
38
2003
2491
1.040
 Why?
Combined Modality Therapy
52
2024
1235
1.020
 Why?
Doxorubicin
24
2025
365
1.020
 Why?
Biomarkers, Tumor
17
2022
1274
0.980
 Why?
Paclitaxel
14
2024
227
0.920
 Why?
Mastectomy
9
2018
136
0.920
 Why?
CTLA-4 Antigen
1
2025
99
0.920
 Why?
Bone Marrow Transplantation
27
1998
286
0.910
 Why?
Bone Neoplasms
7
2025
248
0.860
 Why?
Antibodies, Monoclonal, Humanized
10
2025
804
0.840
 Why?
Antineoplastic Agents, Alkylating
5
2018
73
0.760
 Why?
Female
168
2025
72840
0.750
 Why?
Receptors, Androgen
7
2018
149
0.740
 Why?
Disease-Free Survival
24
2023
687
0.720
 Why?
Humans
226
2025
136783
0.710
 Why?
Middle Aged
112
2025
33200
0.700
 Why?
Antineoplastic Agents, Hormonal
10
2018
161
0.680
 Why?
Maytansine
3
2021
16
0.660
 Why?
Liposarcoma
4
2023
27
0.660
 Why?
Adult
114
2025
37616
0.610
 Why?
Neoplasm Metastasis
23
2024
654
0.600
 Why?
Chemotherapy, Adjuvant
23
2023
390
0.590
 Why?
Dioxoles
2
2015
9
0.570
 Why?
Tetrahydroisoquinolines
2
2015
8
0.570
 Why?
Cyclophosphamide
31
2024
248
0.570
 Why?
Aged
65
2025
23729
0.530
 Why?
Ifosfamide
19
1998
37
0.520
 Why?
Androgen Receptor Antagonists
6
2021
34
0.520
 Why?
Phenylthiohydantoin
5
2017
42
0.520
 Why?
Dasatinib
1
2016
54
0.510
 Why?
Trastuzumab
10
2024
101
0.500
 Why?
Neoplasms, Hormone-Dependent
3
2012
38
0.490
 Why?
Treatment Outcome
43
2024
10764
0.480
 Why?
Drug Administration Schedule
24
2018
783
0.450
 Why?
Carboplatin
21
2016
143
0.450
 Why?
Estrogen Receptor alpha
5
2021
145
0.450
 Why?
Granulocyte Colony-Stimulating Factor
11
2002
74
0.450
 Why?
Carcinoma, Non-Small-Cell Lung
17
2001
1078
0.430
 Why?
Clinical Trials as Topic
19
2018
1043
0.420
 Why?
Estrogens
6
2018
367
0.410
 Why?
Dacarbazine
9
2018
97
0.400
 Why?
Survival Rate
19
2021
1969
0.370
 Why?
Tamoxifen
9
2018
202
0.370
 Why?
Neoplasms
20
2009
2644
0.370
 Why?
Survival Analysis
23
2010
1319
0.360
 Why?
Prognosis
22
2021
4018
0.350
 Why?
Venous Thromboembolism
3
2020
309
0.350
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2013
973
0.350
 Why?
Pyrimidines
3
2020
470
0.350
 Why?
Programmed Cell Death 1 Receptor
2
2025
250
0.350
 Why?
Carcinoma, Intraductal, Noninfiltrating
3
2022
56
0.340
 Why?
Neoplasms, Second Primary
3
2022
115
0.340
 Why?
Antibodies, Monoclonal
9
2024
1428
0.340
 Why?
Dose-Response Relationship, Drug
17
2017
2045
0.340
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
8
1999
152
0.330
 Why?
Taxoids
7
2023
104
0.330
 Why?
Remission Induction
16
2002
287
0.330
 Why?
Breast Neoplasms, Male
3
2018
28
0.320
 Why?
Drug Resistance, Neoplasm
7
2017
800
0.310
 Why?
Gene Expression Regulation, Neoplastic
11
2018
1396
0.300
 Why?
Neoplastic Cells, Circulating
2
2020
80
0.290
 Why?
Mesna
12
1998
16
0.290
 Why?
Sarcoma, Ewing
3
2022
95
0.270
 Why?
Leiomyosarcoma
2
2018
28
0.270
 Why?
Cisplatin
14
2000
318
0.260
 Why?
Immunoconjugates
3
2024
114
0.260
 Why?
Sternum
1
2006
24
0.260
 Why?
Tumor Microenvironment
4
2024
671
0.250
 Why?
Immunohistochemistry
5
2016
1731
0.250
 Why?
Mastectomy, Segmental
2
2009
93
0.240
 Why?
Pyridines
2
2025
505
0.240
 Why?
Chondrosarcoma
1
2025
17
0.240
 Why?
Peripheral Blood Stem Cell Transplantation
2
2002
24
0.240
 Why?
Carcinoma, Ductal
1
2005
11
0.240
 Why?
Melphalan
10
2002
35
0.230
 Why?
Male
66
2025
67361
0.230
 Why?
Transplantation, Autologous
19
2002
237
0.230
 Why?
Isocitrate Dehydrogenase
1
2025
60
0.230
 Why?
Cell Adhesion Molecules
2
2021
181
0.230
 Why?
Protein Kinase Inhibitors
4
2019
916
0.230
 Why?
Lymph Nodes
1
2007
492
0.230
 Why?
Carcinoma
2
2008
236
0.220
 Why?
Glycine
1
2025
175
0.220
 Why?
Risk Reduction Behavior
2
2016
218
0.220
 Why?
Drug Evaluation
19
1998
84
0.220
 Why?
Adjuvants, Immunologic
3
2022
226
0.220
 Why?
Deoxycytidine
4
2020
175
0.210
 Why?
Ribonuclease III
2
2016
40
0.210
 Why?
Ovarian Neoplasms
3
2022
563
0.210
 Why?
Survivors
3
2016
487
0.210
 Why?
Hodgkin Disease
4
2016
139
0.210
 Why?
Thiotepa
13
2002
20
0.210
 Why?
Alkylating Agents
3
2000
24
0.210
 Why?
Triazoles
2
2022
147
0.200
 Why?
Weight Loss
4
2016
775
0.200
 Why?
DEAD-box RNA Helicases
2
2016
76
0.200
 Why?
Behavior Therapy
2
2016
257
0.200
 Why?
Aged, 80 and over
14
2021
7569
0.200
 Why?
Medical Oncology
5
2024
290
0.200
 Why?
Disease Management
5
2020
623
0.200
 Why?
Gene Expression Profiling
6
2017
1768
0.200
 Why?
Employment
1
2024
177
0.200
 Why?
Overweight
3
2016
557
0.190
 Why?
Obesity
4
2018
2975
0.190
 Why?
Mutation
4
2025
3953
0.190
 Why?
Salvage Therapy
6
2010
142
0.190
 Why?
Circulating Tumor DNA
1
2022
34
0.190
 Why?
Hydrazines
1
2022
35
0.190
 Why?
Carcinoma in Situ
2
2012
49
0.190
 Why?
Etoposide
10
2001
157
0.190
 Why?
Referral and Consultation
1
2007
777
0.180
 Why?
Hematologic Diseases
6
2008
62
0.180
 Why?
Emergency Medicine
1
2024
224
0.180
 Why?
Tumor Cells, Cultured
9
2020
953
0.180
 Why?
Liposarcoma, Myxoid
1
2021
10
0.180
 Why?
Sarcoma, Synovial
1
2021
21
0.180
 Why?
Aromatase Inhibitors
4
2021
53
0.180
 Why?
Recombinant Fusion Proteins
1
2024
663
0.180
 Why?
Endpoint Determination
1
2021
77
0.170
 Why?
Sentinel Lymph Node Biopsy
3
2017
115
0.170
 Why?
Cancer Care Facilities
1
2020
38
0.170
 Why?
Indazoles
1
2020
69
0.170
 Why?
Time Factors
12
2020
6792
0.170
 Why?
Leukocytes, Mononuclear
3
2020
556
0.170
 Why?
Hematopoietic Stem Cells
5
1996
400
0.170
 Why?
Cell Separation
3
2017
318
0.170
 Why?
Diphosphonates
1
2020
66
0.160
 Why?
Pyrroles
2
2013
211
0.160
 Why?
Bone Marrow
8
2000
286
0.160
 Why?
Diet
3
2018
1273
0.160
 Why?
Nuclear Medicine
1
2019
9
0.160
 Why?
Antigens, Neoplasm
4
2021
320
0.150
 Why?
Hematology
1
2019
20
0.150
 Why?
Proportional Hazards Models
6
2020
1260
0.150
 Why?
Cell Line, Tumor
9
2017
3399
0.150
 Why?
MCF-7 Cells
5
2017
124
0.150
 Why?
Fluorouracil
7
2013
210
0.150
 Why?
CA-125 Antigen
2
2013
14
0.150
 Why?
Epithelial-Mesenchymal Transition
1
2020
209
0.150
 Why?
Thromboembolism
1
2019
119
0.150
 Why?
Nitriles
5
2017
172
0.150
 Why?
Pulmonary Medicine
1
2019
85
0.150
 Why?
Benzamides
5
2017
217
0.140
 Why?
Bayes Theorem
4
2024
400
0.140
 Why?
Receptor, Fibroblast Growth Factor, Type 1
1
2018
53
0.140
 Why?
Cyclin-Dependent Kinase 4
1
2018
47
0.140
 Why?
Research Design
3
2021
1107
0.140
 Why?
Cyclin-Dependent Kinase 6
1
2018
42
0.140
 Why?
Tissue Inhibitor of Metalloproteinase-3
1
2017
9
0.140
 Why?
Infusions, Intravenous
10
2020
408
0.140
 Why?
Cell Cycle
1
2021
601
0.140
 Why?
Kaplan-Meier Estimate
6
2018
891
0.140
 Why?
Indoles
2
2013
410
0.140
 Why?
Anesthesiology
1
2019
85
0.140
 Why?
Schwann Cells
1
2017
34
0.140
 Why?
Tetrahydronaphthalenes
1
2017
29
0.140
 Why?
Sciatic Nerve
1
2017
58
0.140
 Why?
Microbubbles
1
2017
49
0.140
 Why?
Valine
1
2017
82
0.140
 Why?
Vaccines
1
2022
406
0.140
 Why?
Venous Thrombosis
1
2019
186
0.140
 Why?
Betacoronavirus
1
2020
267
0.130
 Why?
Societies, Medical
2
2019
820
0.130
 Why?
Camptothecin
3
2024
114
0.130
 Why?
Lymph Node Excision
3
2015
170
0.130
 Why?
Amyloid Precursor Protein Secretases
1
2017
80
0.130
 Why?
Axilla
3
2017
47
0.130
 Why?
Sulfonamides
1
2020
512
0.130
 Why?
Androgen Antagonists
2
2015
82
0.130
 Why?
Immunotherapy
2
2018
640
0.130
 Why?
Cancer-Associated Fibroblasts
1
2016
20
0.130
 Why?
Internship and Residency
2
2024
1131
0.130
 Why?
Gonadal Steroid Hormones
1
2018
140
0.130
 Why?
Hematopoietic Cell Growth Factors
2
1995
4
0.130
 Why?
Ultrasonography, Mammary
1
2016
13
0.130
 Why?
Neoplasms, Germ Cell and Embryonal
2
1995
77
0.130
 Why?
Neoplasms, Radiation-Induced
1
2016
92
0.130
 Why?
Thiazoles
1
2016
123
0.130
 Why?
Follow-Up Studies
6
2025
5115
0.120
 Why?
Antibody Specificity
1
2016
189
0.120
 Why?
Lymphatic Metastasis
3
2017
350
0.120
 Why?
Neoplasm Invasiveness
3
2016
507
0.120
 Why?
Ambulatory Care
1
2020
538
0.120
 Why?
Myelin Sheath
1
2017
166
0.120
 Why?
Tumor Suppressor Protein p53
2
2023
530
0.120
 Why?
Maximum Tolerated Dose
1
2016
198
0.120
 Why?
Antibiotics, Antineoplastic
1
2016
130
0.120
 Why?
Neoplastic Stem Cells
2
2017
397
0.120
 Why?
Benzimidazoles
1
2016
168
0.120
 Why?
Quinolines
1
2016
177
0.120
 Why?
Pneumonia, Viral
1
2020
368
0.120
 Why?
Coronavirus Infections
1
2020
359
0.120
 Why?
Pyrazoles
1
2018
423
0.110
 Why?
Recurrence
5
2020
1058
0.110
 Why?
Mammography
1
2016
151
0.110
 Why?
Animals
17
2021
36768
0.110
 Why?
Drug Therapy, Combination
4
2014
1059
0.110
 Why?
Radiotherapy, Adjuvant
5
2016
217
0.110
 Why?
Disease Progression
7
2018
2750
0.110
 Why?
Homeodomain Proteins
2
2018
504
0.110
 Why?
Administration, Oral
4
2020
808
0.110
 Why?
Antibodies
1
2016
412
0.110
 Why?
Brain Edema
1
2014
61
0.110
 Why?
Hepatic Veno-Occlusive Disease
3
2002
14
0.110
 Why?
Young Adult
10
2025
13126
0.110
 Why?
Radiotherapy Dosage
3
1999
267
0.110
 Why?
TOR Serine-Threonine Kinases
1
2017
412
0.110
 Why?
Exercise
2
2015
2038
0.110
 Why?
Vascular Neoplasms
1
2013
18
0.110
 Why?
Comorbidity
5
2017
1611
0.110
 Why?
Clinical Trials, Phase I as Topic
3
2024
51
0.110
 Why?
Radiotherapy
3
2015
201
0.100
 Why?
Testicular Neoplasms
1
1995
110
0.100
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
3
2022
116
0.100
 Why?
Epigenesis, Genetic
2
2018
658
0.100
 Why?
Keratins
2
2017
173
0.100
 Why?
Cellular Reprogramming
1
2014
98
0.100
 Why?
Bridged-Ring Compounds
3
2020
14
0.100
 Why?
Mercaptoethanol
2
1990
11
0.100
 Why?
Mice
12
2021
17731
0.100
 Why?
Adenocarcinoma
6
2015
936
0.100
 Why?
Apoptosis
6
2023
2548
0.100
 Why?
Patient Selection
4
2016
689
0.100
 Why?
Gallium Radioisotopes
1
1992
14
0.100
 Why?
Cell Proliferation
6
2017
2473
0.100
 Why?
Bone Marrow Cells
4
2000
316
0.100
 Why?
Chromatin
1
2016
518
0.100
 Why?
Carmustine
10
2001
50
0.100
 Why?
Adolescent
23
2025
21463
0.100
 Why?
Protein-Tyrosine Kinases
2
2022
434
0.100
 Why?
Anthracyclines
3
2023
48
0.090
 Why?
Lymphoma, Non-Hodgkin
3
2001
87
0.090
 Why?
Methotrexate
4
2002
260
0.090
 Why?
Retrospective Studies
12
2023
15564
0.090
 Why?
Brain Neoplasms
5
2014
1241
0.090
 Why?
Weight Reduction Programs
1
2012
116
0.090
 Why?
Neoplasm, Residual
2
2022
133
0.090
 Why?
RNA, Catalytic
1
2012
187
0.090
 Why?
Risk Assessment
3
2020
3429
0.090
 Why?
Polydeoxyribonucleotides
2
2002
14
0.090
 Why?
Radiosurgery
1
2014
345
0.090
 Why?
Aorta
1
2013
417
0.090
 Why?
Neutropenia
5
2013
146
0.090
 Why?
Age Factors
5
2019
3290
0.090
 Why?
Carcinoma, Lobular
1
2011
49
0.090
 Why?
Neoplasm Grading
3
2017
306
0.090
 Why?
Multivariate Analysis
4
2013
1513
0.090
 Why?
Leukapheresis
4
2001
21
0.090
 Why?
Liver Neoplasms
3
2015
784
0.080
 Why?
Keratin-5
1
2010
50
0.080
 Why?
Angiogenesis Inhibitors
1
2012
226
0.080
 Why?
Practice Patterns, Physicians'
1
2019
1294
0.080
 Why?
Biopsy
3
2018
1126
0.080
 Why?
Peptide Mapping
1
2010
64
0.080
 Why?
Molecular Targeted Therapy
3
2018
413
0.080
 Why?
Electrophoresis, Gel, Two-Dimensional
1
2010
114
0.080
 Why?
Databases, Protein
1
2010
86
0.080
 Why?
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
1
2010
144
0.080
 Why?
Benzenesulfonates
1
2009
22
0.080
 Why?
Postmenopause
2
2017
365
0.080
 Why?
CD146 Antigen
2
2021
41
0.080
 Why?
Urinary Tract
1
1990
51
0.080
 Why?
BRCA2 Protein
1
2009
63
0.080
 Why?
Health Facilities
1
2009
83
0.080
 Why?
Pregnancy Complications, Neoplastic
1
2009
51
0.080
 Why?
Thrombophilia
1
2009
84
0.080
 Why?
Observer Variation
1
2010
345
0.080
 Why?
Patient Care
1
2009
110
0.070
 Why?
Risk Factors
8
2020
10331
0.070
 Why?
United States
9
2023
14660
0.070
 Why?
Perimenopause
1
2008
62
0.070
 Why?
Mice, Nude
3
2017
692
0.070
 Why?
Fibrinolytic Agents
2
2002
272
0.070
 Why?
Bone Marrow Diseases
4
2000
19
0.070
 Why?
In Situ Hybridization
2
2010
315
0.070
 Why?
Fatigue
3
2018
327
0.070
 Why?
Randomized Controlled Trials as Topic
6
2000
1455
0.070
 Why?
In Situ Hybridization, Fluorescence
1
2008
317
0.070
 Why?
Xenograft Model Antitumor Assays
3
2017
864
0.070
 Why?
Blotting, Western
1
2010
1225
0.070
 Why?
Pneumonectomy
3
1997
154
0.060
 Why?
Sputum
1
1988
311
0.060
 Why?
Reproducibility of Results
2
2016
3272
0.060
 Why?
Quality of Life
2
2015
2868
0.060
 Why?
Proto-Oncogene Proteins c-akt
2
2019
436
0.060
 Why?
Clinical Decision-Making
2
2020
318
0.060
 Why?
Neoplasm Proteins
2
2007
432
0.060
 Why?
Life Tables
2
2002
20
0.060
 Why?
Anilides
2
2016
73
0.060
 Why?
New Jersey
1
2024
14
0.060
 Why?
Positron-Emission Tomography
1
2006
295
0.060
 Why?
Colony-Stimulating Factors
3
1988
36
0.060
 Why?
Predictive Value of Tests
2
2016
2030
0.060
 Why?
Enzyme Inhibitors
1
2008
838
0.060
 Why?
Receptor, TIE-2
1
2024
12
0.060
 Why?
Anticoagulants
2
2019
658
0.060
 Why?
Granulocytes
4
1995
80
0.060
 Why?
New York
1
2024
129
0.050
 Why?
Genes, Neoplasm
1
2004
22
0.050
 Why?
Ricin
2
1997
8
0.050
 Why?
Growth Substances
3
1988
147
0.050
 Why?
Oligonucleotide Array Sequence Analysis
3
2012
765
0.050
 Why?
Patient Care Planning
1
2005
154
0.050
 Why?
Forecasting
3
2000
384
0.050
 Why?
MicroRNAs
1
2010
697
0.050
 Why?
Thrombocytopenia
3
2013
199
0.050
 Why?
Magnetic Resonance Imaging
1
2016
3566
0.050
 Why?
Mammaplasty
2
2016
105
0.050
 Why?
Up-Regulation
2
2017
843
0.050
 Why?
Activating Transcription Factor 4
1
2023
20
0.050
 Why?
Signal Transduction
5
2018
5065
0.050
 Why?
Proteasome Inhibitors
1
2023
45
0.050
 Why?
Proto-Oncogene Proteins c-mdm2
1
2023
65
0.050
 Why?
G(M2) Ganglioside
1
2022
1
0.050
 Why?
Injection Site Reaction
1
2022
3
0.050
 Why?
Cyclin E
1
2022
25
0.050
 Why?
Proteomics
1
2010
1108
0.050
 Why?
Clinical Trials, Phase III as Topic
2
2000
105
0.050
 Why?
Transcriptome
2
2023
971
0.050
 Why?
Treatment Failure
2
2001
353
0.050
 Why?
Luminescent Measurements
1
2003
75
0.050
 Why?
France
2
2019
33
0.050
 Why?
Oncogene Proteins
1
2022
59
0.050
 Why?
Ribose
1
2022
24
0.050
 Why?
Blood Transfusion, Autologous
2
1993
17
0.050
 Why?
Proteasome Endopeptidase Complex
1
2023
155
0.050
 Why?
Carbolines
1
2022
32
0.050
 Why?
Heterocyclic Compounds, 4 or More Rings
1
2022
20
0.050
 Why?
Adenosine Diphosphate
1
2022
79
0.050
 Why?
Career Choice
1
2024
215
0.050
 Why?
Class I Phosphatidylinositol 3-Kinases
1
2022
95
0.050
 Why?
Actuarial Analysis
2
1993
27
0.050
 Why?
Oncogenes
1
2022
116
0.050
 Why?
Tomography, X-Ray Computed
2
2015
2677
0.050
 Why?
Colony-Forming Units Assay
4
1996
91
0.050
 Why?
Cell Division
2
2001
796
0.050
 Why?
Gene Expression
2
2020
1499
0.040
 Why?
Carcinoembryonic Antigen
1
2001
39
0.040
 Why?
Phthalazines
1
2021
45
0.040
 Why?
Fellowships and Scholarships
1
2024
306
0.040
 Why?
Prospective Studies
5
2022
7583
0.040
 Why?
Transplantation Immunology
1
2000
34
0.040
 Why?
Clodronic Acid
1
2020
17
0.040
 Why?
Longitudinal Studies
2
2012
2847
0.040
 Why?
Extracellular Matrix
1
2024
527
0.040
 Why?
Phosphatidylinositol 3-Kinases
1
2022
365
0.040
 Why?
Progesterone
1
2002
251
0.040
 Why?
Estradiol
2
2016
518
0.040
 Why?
Ligands
1
2022
664
0.040
 Why?
Topoisomerase I Inhibitors
1
1999
16
0.040
 Why?
Thoracotomy
2
1997
75
0.040
 Why?
Polymerase Chain Reaction
1
2003
1059
0.040
 Why?
Hematopoietic Stem Cell Mobilization
1
1999
22
0.040
 Why?
Leucovorin
2
1997
82
0.040
 Why?
Bone Density Conservation Agents
1
2020
80
0.040
 Why?
Dendritic Cells
2
2000
484
0.040
 Why?
Mechlorethamine
1
2000
60
0.040
 Why?
Myelodysplastic Syndromes
1
2001
135
0.040
 Why?
Drug Resistance
1
1999
169
0.040
 Why?
Neoplasms, Experimental
1
2000
176
0.040
 Why?
Heterocyclic Compounds, 3-Ring
1
2019
32
0.040
 Why?
Receptors, Steroid
1
2019
50
0.040
 Why?
Cluster Analysis
2
2012
495
0.040
 Why?
Piperazines
1
2021
350
0.040
 Why?
Cell Cycle Proteins
1
2022
611
0.040
 Why?
Etanidazole
1
1998
1
0.040
 Why?
Child
8
2022
21968
0.040
 Why?
Leukemia
1
2001
238
0.040
 Why?
Enterocolitis, Pseudomembranous
1
1998
29
0.040
 Why?
Expectorants
1
1998
24
0.040
 Why?
Loss of Function Mutation
1
2018
46
0.040
 Why?
Aurora Kinase A
1
2018
56
0.040
 Why?
Nervous System
2
1997
67
0.040
 Why?
Cross-Over Studies
1
2020
560
0.040
 Why?
Statistics, Nonparametric
1
1999
430
0.040
 Why?
Retreatment
1
2018
72
0.040
 Why?
Mediastinum
1
1998
25
0.040
 Why?
Disease Susceptibility
1
2020
344
0.040
 Why?
Nausea
1
2018
111
0.040
 Why?
Epithelial Cell Adhesion Molecule
1
2017
13
0.040
 Why?
Myelin Basic Protein
1
2017
47
0.040
 Why?
ADAM17 Protein
1
2017
35
0.040
 Why?
Administration, Intravenous
1
2018
154
0.040
 Why?
Extremities
2
1989
129
0.040
 Why?
Bromodeoxyuridine
1
2017
80
0.040
 Why?
Watchful Waiting
1
2018
80
0.030
 Why?
Breast
1
2018
150
0.030
 Why?
SEER Program
1
2018
218
0.030
 Why?
Medicare
1
2023
747
0.030
 Why?
Ganglia, Spinal
1
2017
77
0.030
 Why?
Diarrhea
1
2018
183
0.030
 Why?
Cell Hypoxia
1
1998
225
0.030
 Why?
Double-Blind Method
1
2022
1981
0.030
 Why?
Thorax
1
1997
47
0.030
 Why?
Random Allocation
2
1988
353
0.030
 Why?
Ascorbic Acid
1
2017
126
0.030
 Why?
Phosphoramide Mustards
1
2016
2
0.030
 Why?
Everolimus
1
2017
91
0.030
 Why?
Coculture Techniques
1
2017
239
0.030
 Why?
Heterografts
1
2017
138
0.030
 Why?
Cyclohexanes
1
2016
21
0.030
 Why?
Cohort Studies
4
2001
5718
0.030
 Why?
Immunotoxins
1
1997
55
0.030
 Why?
Cells, Cultured
2
2017
4194
0.030
 Why?
Cytochrome P-450 CYP3A
1
2017
88
0.030
 Why?
Cell Survival
1
2000
1117
0.030
 Why?
Placebos
1
2016
197
0.030
 Why?
Gene Knockdown Techniques
1
2017
326
0.030
 Why?
Fluorescence Resonance Energy Transfer
1
2017
177
0.030
 Why?
Lymphoma, Large B-Cell, Diffuse
1
1998
124
0.030
 Why?
Carcinogenesis
1
2018
217
0.030
 Why?
Injections, Intravenous
2
1993
205
0.030
 Why?
Antineoplastic Agents, Immunological
1
2018
189
0.030
 Why?
Fertility Preservation
1
2016
49
0.030
 Why?
Blood Specimen Collection
1
1995
38
0.030
 Why?
Organoplatinum Compounds
3
1990
46
0.030
 Why?
Antidotes
1
1997
143
0.030
 Why?
Blood Component Transfusion
2
1994
84
0.030
 Why?
Digestive System
1
1995
28
0.030
 Why?
Animals, Newborn
1
2017
843
0.030
 Why?
Genetic Therapy
1
1997
296
0.030
 Why?
Transcriptional Activation
1
2017
378
0.030
 Why?
Mortality
1
1997
357
0.030
 Why?
Vincristine
1
1995
116
0.030
 Why?
Fertility
1
2016
159
0.030
 Why?
Interleukin-3
1
1994
25
0.030
 Why?
Hormones
1
2015
142
0.030
 Why?
Weight Gain
1
2018
518
0.030
 Why?
Kidney
2
1995
1463
0.030
 Why?
Diagnosis, Differential
1
2019
1483
0.030
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2017
251
0.030
 Why?
Pulmonary Fibrosis
3
1993
400
0.030
 Why?
Child, Preschool
6
2013
11069
0.030
 Why?
Leukocyte Count
5
1996
330
0.030
 Why?
Tosyl Compounds
1
2014
15
0.030
 Why?
Odds Ratio
1
2017
1063
0.030
 Why?
Bacterial Infections
1
1996
251
0.030
 Why?
Adipose Tissue
1
2018
629
0.030
 Why?
Drug Discovery
1
2015
141
0.030
 Why?
Hand-Foot Syndrome
1
2013
2
0.030
 Why?
Antioxidants
1
2017
578
0.030
 Why?
Protein Transport
1
2015
442
0.030
 Why?
Capecitabine
1
2013
46
0.030
 Why?
HEK293 Cells
1
2016
728
0.030
 Why?
Transplantation, Heterologous
1
2014
195
0.030
 Why?
Neoplasm Transplantation
1
2014
256
0.030
 Why?
Necrosis
1
2014
244
0.030
 Why?
Alternative Splicing
1
2015
227
0.030
 Why?
Cell Nucleus
1
2016
614
0.030
 Why?
Erythropoietin
1
1994
95
0.030
 Why?
Gene Silencing
1
2014
193
0.030
 Why?
Binding Sites
1
2016
1308
0.030
 Why?
Blood Cells
1
1993
40
0.030
 Why?
Cross-Sectional Studies
1
2024
5417
0.030
 Why?
Nutritional Status
1
2015
344
0.020
 Why?
CD24 Antigen
1
2012
20
0.020
 Why?
Emergency Medical Services
1
2019
548
0.020
 Why?
Recombinant Proteins
5
1997
1354
0.020
 Why?
Anemia
1
1994
170
0.020
 Why?
Sensitivity and Specificity
2
2000
1942
0.020
 Why?
Radionuclide Imaging
1
1992
118
0.020
 Why?
Diet, Reducing
1
2012
88
0.020
 Why?
Energy Intake
1
2015
484
0.020
 Why?
Psychotherapy, Group
1
2012
66
0.020
 Why?
Models, Biological
1
1999
1769
0.020
 Why?
Antigens, CD34
3
1996
88
0.020
 Why?
Hyaluronan Receptors
1
2012
103
0.020
 Why?
Counseling
1
2015
391
0.020
 Why?
Feasibility Studies
4
1998
947
0.020
 Why?
Surveys and Questionnaires
1
2024
5749
0.020
 Why?
Vascular Endothelial Growth Factor Receptor-1
1
2012
71
0.020
 Why?
Mice, SCID
1
2012
367
0.020
 Why?
Pandemics
1
2020
1619
0.020
 Why?
Tumor Burden
1
2012
309
0.020
 Why?
Fluorescent Antibody Technique
2
1990
386
0.020
 Why?
Logistic Models
1
2016
2060
0.020
 Why?
Biopsy, Needle
1
2011
189
0.020
 Why?
Mice, Inbred NOD
1
2012
601
0.020
 Why?
Chromosomes, Human, Pair 9
1
1990
42
0.020
 Why?
Disease Models, Animal
1
2021
4279
0.020
 Why?
Blast Crisis
1
1990
33
0.020
 Why?
Colorado
1
2020
4491
0.020
 Why?
Bilirubin
2
2002
97
0.020
 Why?
Chromosomes, Human, Pair 22
1
1990
45
0.020
 Why?
Immunoblotting
1
2010
307
0.020
 Why?
Health Status
1
2015
781
0.020
 Why?
Pemetrexed
1
2010
33
0.020
 Why?
Glutamates
1
2010
59
0.020
 Why?
Graft Survival
1
1993
533
0.020
 Why?
Magnetics
1
1990
47
0.020
 Why?
Antibodies, Anti-Idiotypic
1
1990
59
0.020
 Why?
Gene Regulatory Networks
1
2012
308
0.020
 Why?
Urologic Diseases
1
1990
41
0.020
 Why?
Guanine
1
2010
79
0.020
 Why?
Multiple Organ Failure
2
2002
127
0.020
 Why?
Cytokines
1
1998
2088
0.020
 Why?
Kidney Diseases
2
1991
406
0.020
 Why?
Real-Time Polymerase Chain Reaction
1
2010
343
0.020
 Why?
Health Behavior
1
2015
756
0.020
 Why?
Microspheres
1
1990
137
0.020
 Why?
RNA, Messenger
1
2017
2831
0.020
 Why?
Spinal Cord Neoplasms
1
1989
37
0.020
 Why?
Chromosome Aberrations
1
1990
155
0.020
 Why?
Cell Movement
1
2014
969
0.020
 Why?
Blood
1
1990
106
0.020
 Why?
Clone Cells
1
1990
266
0.020
 Why?
Pregnancy Trimester, Second
1
2009
80
0.020
 Why?
Promoter Regions, Genetic
1
2014
1250
0.020
 Why?
Central Nervous System Diseases
1
1990
69
0.020
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
1990
121
0.020
 Why?
Hematuria
1
1989
12
0.020
 Why?
Hypertension
1
2018
1284
0.020
 Why?
Lymphoma
1
1990
206
0.020
 Why?
Vinblastine
2
2001
71
0.020
 Why?
False Negative Reactions
1
1988
53
0.020
 Why?
Creatinine
1
1991
498
0.020
 Why?
Rats
1
2017
5628
0.020
 Why?
DNA Methylation
1
2014
644
0.020
 Why?
Pregnancy Trimester, First
1
2009
143
0.020
 Why?
Niacinamide
1
2009
78
0.020
 Why?
Leukopenia
1
1988
31
0.020
 Why?
Immunophenotyping
2
2000
319
0.020
 Why?
Apoptosis Regulatory Proteins
1
2009
188
0.020
 Why?
Phenylurea Compounds
1
2009
95
0.020
 Why?
False Positive Reactions
1
1988
114
0.020
 Why?
Neurons
1
2017
1583
0.020
 Why?
Hospitals, Veterans
1
2009
249
0.020
 Why?
Histones
1
2014
635
0.020
 Why?
Electrophoresis
1
1988
32
0.020
 Why?
Antigens, Differentiation
1
1988
83
0.020
 Why?
Drug Interactions
1
1990
405
0.020
 Why?
Perilipin-1
1
2008
17
0.020
 Why?
Estrogen Receptor Modulators
1
2008
17
0.020
 Why?
Staining and Labeling
1
1988
146
0.020
 Why?
Transfection
1
2010
945
0.020
 Why?
Exercise Therapy
1
2012
434
0.020
 Why?
Macrophages
2
1995
1541
0.020
 Why?
S100 Proteins
1
2008
37
0.020
 Why?
Antigens, Surface
1
1988
153
0.020
 Why?
Gene Expression Regulation
1
2017
2603
0.020
 Why?
Vimentin
1
1988
52
0.020
 Why?
Nervous System Diseases
1
1991
265
0.020
 Why?
Community Health Services
1
2009
228
0.020
 Why?
Androstadienes
1
2008
107
0.020
 Why?
Central Nervous System
1
1990
258
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2417
0.020
 Why?
Sarcoma, Kaposi
1
1988
78
0.020
 Why?
Bone Marrow Purging
2
1996
3
0.020
 Why?
Lung Diseases
2
1992
768
0.020
 Why?
Clinical Trials, Phase II as Topic
2
2000
75
0.020
 Why?
Health Knowledge, Attitudes, Practice
1
2015
1323
0.020
 Why?
Academic Medical Centers
1
2009
497
0.020
 Why?
Biomarkers
1
2018
4158
0.020
 Why?
Risk
2
2000
904
0.020
 Why?
Heart Diseases
1
1990
359
0.020
 Why?
Stem Cell Transplantation
1
2007
177
0.020
 Why?
Gastrointestinal Diseases
1
2008
209
0.020
 Why?
Bevacizumab
1
2006
136
0.020
 Why?
Phosphoproteins
1
2008
338
0.020
 Why?
Immunoglobulin G
1
1990
886
0.010
 Why?
Quality of Health Care
1
2009
627
0.010
 Why?
Body Mass Index
1
2012
2364
0.010
 Why?
Melanoma
2
1988
757
0.010
 Why?
Carrier Proteins
1
2008
768
0.010
 Why?
Ascites
1
2002
46
0.010
 Why?
Brain
1
2014
2669
0.010
 Why?
Phenotype
1
2010
3199
0.010
 Why?
Carcinoma, Lewis Lung
1
2001
15
0.010
 Why?
Carcinoma, Large Cell
1
2001
16
0.010
 Why?
Transplantation Conditioning
1
2002
170
0.010
 Why?
Hemorrhage
2
1998
723
0.010
 Why?
Phytohemagglutinins
1
2000
30
0.010
 Why?
CD4-CD8 Ratio
1
2000
22
0.010
 Why?
Hypersensitivity, Delayed
1
2000
28
0.010
 Why?
Lymphocyte Culture Test, Mixed
1
2000
50
0.010
 Why?
Drug Synergism
1
2001
378
0.010
 Why?
Microcomputers
1
2000
16
0.010
 Why?
Skin Tests
1
2000
101
0.010
 Why?
Graft vs Host Disease
1
2002
249
0.010
 Why?
Louisiana
1
2000
29
0.010
 Why?
Philadelphia
1
2000
49
0.010
 Why?
Immunoglobulins
1
2000
171
0.010
 Why?
Automation
1
2000
95
0.010
 Why?
Immunity
1
2000
144
0.010
 Why?
Personnel Selection
1
1980
78
0.010
 Why?
Lipopolysaccharide Receptors
1
1999
85
0.010
 Why?
Marriage
1
1980
121
0.010
 Why?
Lung
1
1992
4065
0.010
 Why?
Thalassemia
1
1998
7
0.010
 Why?
Interleukin-4
1
1999
217
0.010
 Why?
Heart Failure
1
1992
2228
0.010
 Why?
Receptors, Purinergic P1
1
1998
26
0.010
 Why?
Multicenter Studies as Topic
1
2000
307
0.010
 Why?
Microscopy, Fluorescence
1
2000
397
0.010
 Why?
Reference Values
1
2000
817
0.010
 Why?
Pilot Projects
2
1994
1697
0.010
 Why?
Acute Disease
1
2001
1006
0.010
 Why?
Infant, Newborn
1
2009
6046
0.010
 Why?
Filgrastim
1
1997
8
0.010
 Why?
Killer Cells, Natural
1
2000
445
0.010
 Why?
Adenoviruses, Human
1
1996
27
0.010
 Why?
Heparin
1
1998
258
0.010
 Why?
Lymphoma, B-Cell
1
1998
105
0.010
 Why?
Tissue Plasminogen Activator
1
1998
225
0.010
 Why?
Pregnancy
1
2009
6731
0.010
 Why?
Freezing
1
1996
91
0.010
 Why?
Lymphocyte Depletion
1
1996
134
0.010
 Why?
Lymphocyte Activation
1
2000
1150
0.010
 Why?
Genes, Reporter
1
1996
268
0.010
 Why?
Carcinoma, Squamous Cell
1
2001
682
0.010
 Why?
Drug Tolerance
1
1995
105
0.010
 Why?
Reticulocyte Count
1
1994
6
0.010
 Why?
Kidney Function Tests
1
1995
159
0.010
 Why?
Topotecan
1
1994
13
0.010
 Why?
Incidence
1
2001
2788
0.010
 Why?
Antigens, CD
1
1996
522
0.010
 Why?
Registries
1
2002
2015
0.010
 Why?
Liver
1
2002
1938
0.010
 Why?
Urinary Bladder Diseases
1
1993
19
0.010
 Why?
Glioblastoma
1
1996
343
0.010
 Why?
Heart
1
1997
656
0.010
 Why?
Boston
1
1993
91
0.010
 Why?
Flow Cytometry
1
1996
1181
0.010
 Why?
Chromatography, High Pressure Liquid
1
1995
591
0.010
 Why?
Iron
1
1994
311
0.010
 Why?
Palliative Care
1
1998
743
0.010
 Why?
Cell Line
1
1996
2836
0.010
 Why?
Immunologic Factors
1
1993
237
0.010
 Why?
Cystitis
1
1990
22
0.010
 Why?
Metabolic Clearance Rate
1
1989
116
0.000
 Why?
Introns
1
1990
256
0.000
 Why?
Platinum
1
1989
49
0.000
 Why?
Prostatic Neoplasms
1
1996
1031
0.000
 Why?
Drug Combinations
1
1990
344
0.000
 Why?
Brain Diseases
1
1990
141
0.000
 Why?
Macrophage-1 Antigen
1
1988
28
0.000
 Why?
Bone Marrow Examination
1
1988
5
0.000
 Why?
Erythrocyte Count
1
1988
19
0.000
 Why?
Platelet Count
1
1988
86
0.000
 Why?
Methods
1
1988
65
0.000
 Why?
Pelvic Neoplasms
1
1988
26
0.000
 Why?
Erythroblasts
1
1988
19
0.000
 Why?
Infant
1
2002
9442
0.000
 Why?
DNA Damage
1
1990
418
0.000
 Why?
Acute Kidney Injury
1
1995
811
0.000
 Why?
Fever
1
1988
307
0.000
 Why?
In Vitro Techniques
1
1988
1089
0.000
 Why?
Pneumonia
1
1992
638
0.000
 Why?
Statistics as Topic
1
1987
311
0.000
 Why?
Elias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (664) concept(s)
_
Co-Authors Expand Description
See all (60) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)